Royal Bank of Canada’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-35
| Closed | -$1K | – | 7585 |
|
|
2025
Q4 | $1K | Sell |
35
-14,419
| -100% | -$448K | ﹤0.01% | 7036 |
|
|
2025
Q3 | $373K | Buy |
14,454
+16
| +0.1% | +$209 | ﹤0.01% | 4697 |
|
|
2025
Q2 | $115K | Buy |
14,438
+13,979
| +3,046% | +$107K | ﹤0.01% | 5545 |
|
|
2025
Q1 | $4K | Buy |
+459
| New | +$4.51K | ﹤0.01% | 6424 |
|
|
2024
Q4 | – | Sell |
-411
| Closed | -$7K | – | 7184 |
|
|
2024
Q3 | $7K | Buy |
411
+25
| +6% | +$506 | ﹤0.01% | 6433 |
|
|
2024
Q2 | $10K | Buy |
386
+190
| +97% | +$8.78K | ﹤0.01% | 6347 |
|
|
2024
Q1 | $14K | Sell |
196
-961
| -83% | -$134K | ﹤0.01% | 6072 |
|
|
2023
Q4 | $231K | Buy |
1,157
+622
| +116% | +$77K | ﹤0.01% | 4980 |
|
|
2023
Q3 | $71K | Buy |
535
+139
| +35% | +$22.7K | ﹤0.01% | 5585 |
|
|
2023
Q2 | $59K | Buy |
396
+185
| +88% | +$28.8K | ﹤0.01% | 5693 |
|
|
2023
Q1 | $31K | Sell |
211
-163
| -44% | -$33K | ﹤0.01% | 5857 |
|
|
2022
Q4 | $59K | Buy |
374
+334
| +835% | +$53.5K | ﹤0.01% | 5783 |
|
|
2022
Q3 | $8K | Buy |
40
+22
| +122% | +$4.16K | ﹤0.01% | 6546 |
|
|
2022
Q2 | $3K | Sell |
18
-146
| -89% | -$19.5K | ﹤0.01% | 6849 |
|
|
2022
Q1 | $29K | Sell |
164
-396
| -71% | -$74.8K | ﹤0.01% | 6405 |
|
|
2021
Q4 | $164K | Buy |
560
+337
| +151% | +$90.1K | ﹤0.01% | 5528 |
|
|
2021
Q3 | $55K | Buy |
223
+69
| +45% | +$18.2K | ﹤0.01% | 6104 |
|
|
2021
Q2 | $39K | Buy |
154
+73
| +90% | +$13.6K | ﹤0.01% | 6205 |
|
|
2021
Q1 | $14K | Buy |
81
+35
| +76% | +$5.77K | ﹤0.01% | 6644 |
|
|
2020
Q4 | $8K | Buy |
46
+44
| +2,200% | +$9.57K | ﹤0.01% | 6486 |
|
|
2020
Q3 | $0 | Buy |
2
+1
| +100% | +$222 | ﹤0.01% | 6882 |
|
|
2020
Q2 | $0 | Sell |
1
-63
| -98% | -$9.74K | ﹤0.01% | 6854 |
|
|
2020
Q1 | $11K | Buy |
64
+51
| +392% | +$11.6K | ﹤0.01% | 5800 |
|
|
2019
Q4 | $3K | Buy |
+13
| New | +$2.39K | ﹤0.01% | 6497 |
|
Royal Bank of Canada's RAPT Position: Q1 2026 in Review
Royal Bank of Canada sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 35 shares — an estimated $1K sold.
Royal Bank of Canada first reported a position in RAPT in Q4 2019 and held it in 24 quarters. The position peaked at $373K in Q3 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Royal Bank of Canada reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Royal Bank of Canada sold 35 RAPT Therapeutics shares in Q1 2026, an estimated $1K.
- Royal Bank of Canada first reported a position in RAPT Therapeutics in Q4 2019 and held it in 24 quarters.
- Royal Bank of Canada's RAPT Therapeutics position peaked at $373K in Q3 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.